,
14 tweets,
8 min read
Read on Twitter
👉👉👉The @CDCgov clarification appears in an article in @NEJM here nejm.org/doi/full/10.10…
👉👉👉with an accompanying press release: cdc.gov/media/releases…
👉👉👉with an accompanying press release: cdc.gov/media/releases…
👉👉👉A quick way to see most of the article, a separate letter issued by the CDC Director @CDCDirector and the @US_FDA warning is to go here: …lthprofessionalsforpatientsinpain.org
👉👉👉For the clarification that the @CDCgov guideline does not apply to #SickleCell and #Cancer and that, “The Guideline is not intended to deny any patients who suffer with #ChronicPain from #Opioid therapy as an option for pain management,” see ajmc.com/newsroom/oncol…
Here is some helpful press:
Medpage medpagetoday.com/publichealthpo…
Medpage medpagetoday.com/publichealthpo…
STATnews, statnews.com/2019/04/26/no-…
Forbes forbes.com/sites/sallysat…
The Hill thehill.com/opinion/health…
Tonic/Vice tonic.vice.com/en_us/article/…
If it isn't clear: there were four separate actions: listed below chronologically:
1/April 9 warning about the dangers of abruptly tapering a patient down or off of opioids (including increased pain, and label change issued by the @US_FDA fda.gov/drugs/drug-saf… 
2/ An April 10 letter from @CDCDirector stating the the Guideline does not support mandatory or abrupt tapering of a patient who currently uses opioids and that the only relevant inquiry is if benefits exceed risks for current patients. img1.wsimg.com/blobby/go/3d70…
3/ An April 9 letter to cancer doctors and hematologists stating that the guideline exempted patients with sickle cell and cancer and yet has been used in ways that limit their access to care.
4/ The detailed explanation of the ways in which the duration (3-7 days for acute pain) and dosage (50-90 MME) guidance from the Guideline have been misapplied by policymakers as hard edits or used as the basis for mandatory tapering in @NEJM.
